Skip to content
Screener

Total Liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$65.32B-15.4%
Gilead Sciences logo
Gilead SciencesGILD
$535M
Climb Bio, Inc. logo
Climb Bio, Inc.CLYM
$4.29M-41.7%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
$21.13M+3.8%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$179.49M-14.1%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$117.08M-4.5%

Other financials

Income statement

See full
Operating income-$41.4M+12.7%
Net income-$39.7M+11.0%
EPS (diluted)-$0.66+35.9%

Balance sheet

See full
Cash & equivalents$32.2M-43.4%
Total debt$9.2M+32.1%
Total equity$195.6M-12.7%
Total assets$257.0M-1.4%

Cash flow

See full
Operating cash flow-$41.6M+7.4%
CapEx$2.0K-98.0%
Free cash flow-$33.5M+10.8%

Valuation

See full
Market cap$483.93M+261%
Enterprise value$460.9M+433%

Returns & leverage

See full
Return on equity-74.5%+74.4pp
Debt / equity0.0×
Current ratio8.1×+0.7×

Where this comes from

Reported directly by Kyverna Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:08 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219397
Line itemMarch 31, 2026December 31, 2025
Total current liabilities29,67436,487
Operating lease liabilities, net of short-term portion6,958320
Term loan24,81224,743
Total liabilities61,44461,550
Commitments and contingencies (Note 7)
Stockholders’ equity
Preferred stock, 10,000,000 shares authorized, $0.00001 par value, no shares issued and outstanding at March 31, 2026 and December 31, 2025
Common stock, $0.00001 par value; 490,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 60,532,500 and 60,389,893 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively.11

Item 1. Financial Statements (unaudited)

FAQ

What is Kyverna Therapeutics, Inc.'s total liabilities?
Kyverna Therapeutics, Inc. (KYTX) reported total liabilities of $61.44M in Q1 2026.
How has Kyverna Therapeutics, Inc.'s total liabilities changed year-over-year?
Kyverna Therapeutics, Inc.'s total liabilities increased by 67.7% year-over-year, from $36.65M to $61.44M.
What is the long-term trend for Kyverna Therapeutics, Inc.'s total liabilities?
Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s total liabilities has grown at a 53.8% compound annual growth rate (CAGR), from $26.02M to $61.55M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Kyverna Therapeutics, Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude